Nephrocare Health Services AGM scheduled on Aug 12, 2026
Nephrocare Health Services Limited has announced its 17th Annual General Meeting for August 12, 2026, to be held virtually. The meeting will address the adoption of audited financial statements for the year ended March 31, 2026, and the re-appointment of Mr. Gaurav Sharma as Director. Shareholders will vote on the 'NephroPlus Employee Stock Option Scheme – 2026', involving up to 20,06,814 options, and clarificatory amendments to the remuneration of Chairman & Managing Director Mr. Vikram Vuppala. The AGM also seeks approval for the Promote Incentive Arrangement involving the Founder Promoter and specific investors.

*this image is generated using AI for illustrative purposes only.
Nephrocare Health Services Limited has scheduled its 17th Annual General Meeting (AGM) for Wednesday, August 12, 2026, at 2:30 P.M. IST through Video Conferencing (VC) and Other Audio Visual Means (OAVM). The meeting will be conducted entirely through virtual mode in compliance with the Companies Act, 2013, and relevant SEBI regulations. The company has fixed Wednesday, August 5, 2026, as the cut-off date to determine the eligibility of members to participate in the AGM and avail of remote e-voting facilities. The Register of Members and Share Transfer Books will remain closed from August 6, 2026, to August 12, 2026.
The agenda for the meeting includes the adoption of audited financial statements for the financial year ended March 31, 2026, and the re-appointment of Mr. Gaurav Sharma as a Nominee Director. Shareholders will also vote on special resolutions to approve the 'NephroPlus Employee Stock Option Scheme – 2026' and to extend its benefits to employees of subsidiary and associate companies. The scheme proposes the grant of up to 20,06,814 options, exercisable into equity shares of ₹ 2 each.
Additionally, the meeting seeks approval for clarificatory amendments to the remuneration framework of Mr. Vikram Vuppala, Chairman & Managing Director. The amendments aim to expressly define the performance-linked variable remuneration component based on 'Audited Adjusted Consolidated Operating EBITDA' without altering the overall remuneration structure or limits. Another special business item involves the approval of the Promote Incentive Arrangement between the Founder Promoter and certain shareholders, which does not involve any financial obligation for the company.
Remote e-Voting Schedule
Members entitled to vote may cast their ballots electronically through the remote e-voting facility provided by National Securities Depository Limited (NSDL). The remote e-voting period commences prior to the meeting and concludes the day before the AGM.
| Particulars | Details |
|---|---|
| Remote e-Voting start date and time | Saturday, August 8, 2026 at 09:00 AM IST |
| Remote e-Voting end date and time | Tuesday, August 11, 2026 at 05:00 PM IST |
Members who have already cast their votes via remote e-voting may attend the AGM but will not be entitled to vote again during the meeting. The remote e-voting mode will be disabled by NSDL after the specified end time.
Participation and Technical Support
Shareholders can attend the AGM by logging into the NSDL e-voting system. Detailed procedures for accessing the meeting and casting votes are outlined in the AGM Notice. Members who have acquired shares after the dispatch of the notice but hold them as on the cut-off date are advised to contact the company for the necessary login credentials.
For technical assistance regarding login or e-voting, shareholders holding securities in demat mode with NSDL may contact evoting@nsdl.com or call 022-4886 7000. Those holding shares with CDSL may reach out to helpdesk.evoting@cdslindia.com or call the toll-free number 1800-21-09911.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE428V01029/4470afcc4be04eb5.pdf
Historical Stock Returns for Nephrocare Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.20% | +9.70% | +4.80% | +34.75% | +46.38% | +46.38% |
How will the issuance of over 2 million new stock options impact existing shareholder dilution and earnings per share?
What specific operational metrics will be used to calculate 'Audited Adjusted Consolidated Operating EBITDA' for the Chairman's performance-linked pay?
Does the re-appointment of the Nominee Director signal a strategic shift in the company's partnership or governance structure?


































